Antibody-based therapeutic strategies for malignant lymphomas
Antibody-based therapies have dramatically changed the course of disease in malignant lymphoma. Induction therapy has progressed from monotherapy to immunochemotherapy and radioimmunotherapy. In addition, maintenance treatment is now part of the standard treatment. A large number of antibodies against various targets is in routine use or currently tested in clinical trials. Second and third generation antibodies have improved cell killing properties and promise higher effectiveness. These new developments as well as upcoming strategies against novel targets in lymphoma are reviewed.